Kyowa Kirin Co. Ltd - Strategy, SWOT and Corporate Finance Report
Summary
Kyowa Kirin Co. Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company.
Key Highlights
Kyowa Kirin Co. Ltd (Kyowa Kirin or 'the company'), a subsidiary of Kirin Holdings Company Limited, is a provider of pharmaceuticals and bio-chemicals. It is primarily involved in the development and distribution of biotechnological products with major focus on oncology, nephrology, and central nervous systems. Its product portfolio includes antihistamine agents, calcium channel blockers, antibodies, glycoprotein, human erythropoietin, oral calcimimetics agents, agent for secondary hyperparathyroidism, and other drugs. The company offers its products under the brands: Leunase, Adriacin, Navelbine, Moventig, Coniel, Gran, Peglasta, Potelifeo, Neulasta, ESPO, Orkedia, Pecfent, Regpara, Romiplate, Sancuso, Allelock and Abstral. These products are used to treat hypertension, allergic reactions, anemia and behavioral disorders and others. The company is headquartered in Tokyo, Japan
Scope
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook